Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study
Frontiers in Immunology · 2024
DOI: 10.3389/fimmu.2024.1482005 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Frontiers in Immunology, 2024. Verfasst von Na Zhou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Antibodies, Monoclonal, Humanized, Esophageal Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The application of neoadjuvant immunotherapy in the treatment of esophageal cancer needs further exploration. This study aimed to investigate the safety and effectiveness of tislelizumab, an anti-PD-1 antibody, combined with chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (LA-ESCC).
Methods
In this phase II study, patients with clinical stages of II-IVA (T3-T4 and/or node positive) potentially resectable LA-ESCC were enrolled. Patients received neoadjuvant tislelizumab and chemotherapy every 3 weeks for 4 cycles before surgery and adjuvant tislelizumab for 9 months. The primary endpoint was pathological complete response (pCR) rate. Secondary endpoints included R0 resection, disease free survival (DFS), adverse events (AE), and biomarkers for predicting efficacy.
Results
The study included 30 patients. 25 patients completed neoadjuvant chemoimmunotherapy and underwent surgery, 96% with R0 resection. The pCR and MPR rate was 44% and 52%. The 6-month and 1-year DFS rate was 100% and 75.3%. 43.3% patients experienced severe (grade 3-4) treatment-related adverse events (TRAEs) and 5 patients developed severe immune-related adverse events (irAEs). Further exploration found that a group of peripheral lymphocyte subsets increased significantly after 2 cycles of neoadjuvant therapy in patients who achieved pCR, suggesting the importance of dynamic monitoring of circulating lymphocyte.
Conclusions
The combination of perioperative tislelizumab and neoadjuvant chemotherapy has achieved an encouraging pCR rate and demonstrated a manageable safety profile in patients with potentially resectable ESCC. Clinical Trial Registration https://www.chictr.org.cn/ , identifier ChiCTR2100043772.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, China.
- Department of Gastroenterology, Peking Union Medical College Hospital, Beijing, China.
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Beijing, China.
- Department of Pathology, Peking Union Medical College Hospital, Beijing, China.
- Department of Radiation Oncology, Peking Union Medical College Hospital, Beijing, China.
Zitieren
APA
Zhou, N., Hua, Y., Ge, Y., Wang, Q., Wang, C., He, J., Zhao, L., Yu, S., Yan, J., Zhao, L., Li, L., & Bai, C. (2024). Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2024.1482005
Vancouver
Zhou N, Hua Y, Ge Y, Wang Q, Wang C, He J, et al. Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study. Frontiers in Immunology. 2024. doi:10.3389/fimmu.2024.1482005
BibTeX
@article{Zhou2024,
author = {Zhou, Na and Hua, Yuwei and Ge, Yuping and Wang, Qiang and Wang, Chenyu and He, Jia and Zhao, Luo and Yu, Shuangni and Yan, Junfang and Zhao, Lin and Li, Li and Bai, Chunmei},
title = {Perioperative tislelizumab with four cycles of neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma: a phase 2 study},
journal = {Frontiers in Immunology},
year = {2024},
doi = {10.3389/fimmu.2024.1482005}
}
EUVIMED